X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Company intends to use the net proceeds from the offering to advance the commercial growth of its aesthetics portfolio, including DAXXIFY (daxibotulinumtoxinA-Lanm), which is being used for the treatment of moderate to severe glabellar lines.
Lead Product(s): Daxibotulinumtoxin A
Therapeutic Area: Dermatology Product Name: Daxxify
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Barclays
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 04, 2024
Details:
Daxiffy (daxibotulinumtoxinA-lanm) is an acetylcholine release inhibitor and neuromuscular blocking agent. It is being evaluated in Phase 3 clinical trials for the treatment of cervical dystonia in adults.
Lead Product(s): Daxibotulinumtoxin A
Therapeutic Area: Neurology Product Name: Daxxify
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2024
Details:
Daxxify (daxibotulinumtoxina-lanm) for injection is the first and only peptide-formulated, long-lasting neuromodulator, designed for the treatment of cervical dystonia in adults.
Lead Product(s): DaxibotulinumtoxinA-lanm
Therapeutic Area: Neurology Product Name: Daxxify
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 14, 2023
Details:
Daxxify® (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator or procerus muscle activity in adult patients.
Lead Product(s): DaxibotulinumtoxinA-lanm
Therapeutic Area: Dermatology Product Name: Daxxify
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
Daxxify® (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator or procerus muscle activity in adult patients.
Lead Product(s): DaxibotulinumtoxinA-lanm
Therapeutic Area: Dermatology Product Name: Daxxify
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
DAXXIFY™ (daxibotulinumtoxinA-lanm) for injection is a long-lasting peptide-formulated neuromodulator product for use in adults for the temporary improvement of moderate to severe frown lines. DAXXIFY™ has been proven to be effective, and generally safe and well tolerated.
Lead Product(s): DaxibotulinumtoxinA-lanm
Therapeutic Area: Dermatology Product Name: Daxxify
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
Details:
Revance will use the proceeds for developing and commercializing innovative aesthetic and therapeutic offerings, including DAXXIFY™ (daxibotulinumtoxinA-lanm) for injection, the RHA® collection of dermal fillers.
Lead Product(s): Daxibotulinumtoxin A
Therapeutic Area: Dermatology Product Name: Daxxify
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $230.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 15, 2022
Details:
The Company intends to use the net proceeds from the offering to fund the commercialization of DAXXIFY (DaxibotulinumtoxinA-lanm), the RHA® Collection of dermal fillers and OPUL®, and for working capital, research and development and general corporate purposes.
Lead Product(s): DaxibotulinumtoxinA-lanm
Therapeutic Area: Dermatology Product Name: Daxxify
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 12, 2022
Details:
Approved label includes full 36-week efficacy data from Phase 3 SAKURA clinical program, positioning DAXXIFY (DaxibotulinumtoxinA) as first and only long-acting neuromodulator that demonstrates median duration of six months and up to nine months for some patients.
Lead Product(s): DaxibotulinumtoxinA-lanm
Therapeutic Area: Dermatology Product Name: Daxxify
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Details:
DaxibotulinumtoxinA for Injection, is next-generation product aiming to establish a new, premium, long-lasting neuromodulator category. DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA and is currently under regulatory review.
Lead Product(s): Daxibotulinumtoxin A
Therapeutic Area: Dermatology Product Name: Daxi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
